Chronic pain was most common patient-reported qualifying condition, accounting for 64.5 and 31.9% in 2016 and 2024.

Polypharmacy involving prescription medications affected more than one-third of older adults in 2021 to 2023, according to a ...

The Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve (Edward Lifesciences) for pediatric patients with congenital heart ...

The expanded indication for mavacamten offers a novel targeted medical therapy for pediatric patients aged 12 years and older with symptomatic oHCM, backed by data from the phase 3 SCOUT-HCM trial.

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Highest ASCVD risk at follow-up seen for those who remained in or transitioned into low exposure categories over one year ...

A powerful new lab-made opioid is moving through the illegal US drug supply, and federal officials warn it could keep spreading. The drug, called cychlorphine, may be up to 10 times stronger than ...